Table 3. Donor lymphocyte infusions Pt .... | American Society of Hematology

Table 3.

Donor lymphocyte infusions

Pt	Donor	Indication	After HCT chemotherapy	CD3⁺ cell dose	Response	GVHD	Outcome (cause of death)	Follow-up, mo
1	MR	MC	—	1 × 10⁶	Yes	Yes	Alive, CR	16+
2	MR	MC	—	1 × 10⁶	NA	No	Alive, CR	10+
3	MR	MC	—	1 × 10⁶	Yes	No	Alive, CR	10+
4	MR	MC	—	1 × 10⁶	Yes	No	Alive, CR	48+
5	MR	MC, then CRel	—	1 × 10⁶, 3 × 10⁶, 1 × 10⁷, 3 × 10⁷	No	No	Alive, PD	63+
6	MR	MC, then CRel	Fludarabine + chlorambucil	1 × 10⁶, 3 × 10⁶, 3 × 10⁷	No	Yes	Alive, PD	29+
7	MR	MC + MRel	—	1 × 10⁶, 3 × 10⁶, 1 × 10⁷, 3 × 10⁷, 1 × 10⁸	No	No	Alive, PD	61+
8	MU	MC + CRel	—	1 × 10⁶	Yes	Yes	Died (GVHD)	22
9	MR	MC + RD	—	1 × 10⁶, 3 × 10⁶, 1 × 10⁷, 3 × 10⁷	Yes	No	Alive, CR	62+
10	MR	CRel	CHOP	1 × 10⁷, 3 × 10⁷, 1 × 10⁸	No	No	Alive, PD	16+
11	MR	CRel	CHOP	1 × 10⁷, 3 × 10⁷	Yes	Yes	Alive, CR	40+
12	MR	CRel	COP	1 × 10⁸	No	Yes	Died (PD)	13
13	MU	CRel	CMOP, rituximab, alemtuzumab	1 × 10⁶, 1 × 10⁷	No	No	Died (pneumonia)	16
14	MR	CRel	Alemtuzumab, chlorambucil	1 × 10⁶, 1 × 10⁷	No	No	Died (PD)	13
15	MU	CRel	—	3 × 10⁶, 1 × 10⁷, 3 × 10⁷	Yes	Yes	Alive, CR	51+
16	MU	CRel	—	1 × 10⁷	No	No	Died (PD)	21
17	mMU	RD	—	1 × 10⁶, 1 × 10⁷	Yes	Yes	Died (GVHD)	5
18	MU	RD	—	1 × 10⁷, 3 × 10⁷	Yes	Yes	Alive, PR	21+

Pt	Donor	Indication	After HCT chemotherapy	CD3⁺ cell dose	Response	GVHD	Outcome (cause of death)	Follow-up, mo
1	MR	MC	—	1 × 10⁶	Yes	Yes	Alive, CR	16+
2	MR	MC	—	1 × 10⁶	NA	No	Alive, CR	10+
3	MR	MC	—	1 × 10⁶	Yes	No	Alive, CR	10+
4	MR	MC	—	1 × 10⁶	Yes	No	Alive, CR	48+
5	MR	MC, then CRel	—	1 × 10⁶, 3 × 10⁶, 1 × 10⁷, 3 × 10⁷	No	No	Alive, PD	63+
6	MR	MC, then CRel	Fludarabine + chlorambucil	1 × 10⁶, 3 × 10⁶, 3 × 10⁷	No	Yes	Alive, PD	29+
7	MR	MC + MRel	—	1 × 10⁶, 3 × 10⁶, 1 × 10⁷, 3 × 10⁷, 1 × 10⁸	No	No	Alive, PD	61+
8	MU	MC + CRel	—	1 × 10⁶	Yes	Yes	Died (GVHD)	22
9	MR	MC + RD	—	1 × 10⁶, 3 × 10⁶, 1 × 10⁷, 3 × 10⁷	Yes	No	Alive, CR	62+
10	MR	CRel	CHOP	1 × 10⁷, 3 × 10⁷, 1 × 10⁸	No	No	Alive, PD	16+
11	MR	CRel	CHOP	1 × 10⁷, 3 × 10⁷	Yes	Yes	Alive, CR	40+
12	MR	CRel	COP	1 × 10⁸	No	Yes	Died (PD)	13
13	MU	CRel	CMOP, rituximab, alemtuzumab	1 × 10⁶, 1 × 10⁷	No	No	Died (pneumonia)	16
14	MR	CRel	Alemtuzumab, chlorambucil	1 × 10⁶, 1 × 10⁷	No	No	Died (PD)	13
15	MU	CRel	—	3 × 10⁶, 1 × 10⁷, 3 × 10⁷	Yes	Yes	Alive, CR	51+
16	MU	CRel	—	1 × 10⁷	No	No	Died (PD)	21
17	mMU	RD	—	1 × 10⁶, 1 × 10⁷	Yes	Yes	Died (GVHD)	5
18	MU	RD	—	1 × 10⁷, 3 × 10⁷	Yes	Yes	Alive, PR	21+

Pt indicates patient number; HCT, hematopoietic cell transplantation; MR, matched related; MC, mixed chimerism; CR, complete remission; NA, not available; CRel, clinical relapse; PD, progressive disease; MRel, molecular relapse; MU, matched unrelated; GVHD, graft-versus-host disease; RD, residual disease; CHOP, cyclophosphamide-doxorubicin-vincristine-prednisone; COP, cyclophosphamide-vincristine-prednisone; CMOP, cyclophosphamide-mitoxantrone-vincristine-prednisone; mMU, mismatched unrelated; PR, partial remission.

View Large

This Feature Is Available To Subscribers Only